Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikhil Amin

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
The Journal of Allergy and Clinical Immunology. in Practice|October 10, 2021
Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal PolypsJoaquim Mullol, Claus Bachert, Nikhil Amin, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2024
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthmaLeonard B Bacharier, Ian D Pavord, Jorge F Maspero, et al.
Advances in Therapy|May 5, 2018
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe AsthmaWilliam W Busse, Jorge F Maspero, Klaus F Rabe, et al.
Rhinology|November 1, 2019
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNPClaus Bachert, S James Zinreich, Peter W Hellings, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 13, 2023
Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE StudyLeonard B Bacharier, Theresa W Guilbert, Constance H Katelaris, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 19, 2021
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthmaTanya M Laidlaw, Claus Bachert, Nikhil Amin, et al.
Nature Medicine|May 4, 2023
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trialsGil Yosipovitch, Nicholas Mollanazar, Sonja Ständer, et al.
Allergy|July 16, 2019
Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposisClaus Bachert, Peter W Hellings, Joaquim Mullol, et al.
The Lancet. Respiratory Medicine|July 24, 2021
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trialKlaus F Rabe, Bartolome R Celli, Michael E Wechsler, et al.
The New England Journal of Medicine|October 27, 2021
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe AsthmaMichael E Wechsler, Marcella K Ruddy, Ian D Pavord, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
The Journal of Allergy and Clinical Immunology. in Practice|October 10, 2021
Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal PolypsJoaquim Mullol, Claus Bachert, Nikhil Amin, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2024
Blood eosinophils and fractional exhaled nitric oxide are prognostic and predictive biomarkers in childhood asthmaLeonard B Bacharier, Ian D Pavord, Jorge F Maspero, et al.
Advances in Therapy|May 5, 2018
Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe AsthmaWilliam W Busse, Jorge F Maspero, Klaus F Rabe, et al.
Rhinology|November 1, 2019
Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNPClaus Bachert, S James Zinreich, Peter W Hellings, et al.
The Journal of Allergy and Clinical Immunology. in Practice|December 13, 2023
Dupilumab Improves Lung Function Parameters in Pediatric Type 2 Asthma: VOYAGE StudyLeonard B Bacharier, Theresa W Guilbert, Constance H Katelaris, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|January 19, 2021
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthmaTanya M Laidlaw, Claus Bachert, Nikhil Amin, et al.
Nature Medicine|May 4, 2023
Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trialsGil Yosipovitch, Nicholas Mollanazar, Sonja Ständer, et al.
Allergy|July 16, 2019
Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposisClaus Bachert, Peter W Hellings, Joaquim Mullol, et al.
The Lancet. Respiratory Medicine|July 24, 2021
Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trialKlaus F Rabe, Bartolome R Celli, Michael E Wechsler, et al.
The New England Journal of Medicine|October 27, 2021
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe AsthmaMichael E Wechsler, Marcella K Ruddy, Ian D Pavord, et al.
Pageof 6